Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Vir Biotechnology Rose as Much as 100.1% Today

By Maxx Chatsko - Updated Feb 27, 2020 at 1:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced a partnership in its efforts to develop monoclonal antibodies capable of neutralizing the novel coronavirus strain.

What happened

Shares of Vir Biotechnology (VIR 2.69%) more than doubled today after the company announced a collaboration with WuXi Biologics. The pair will work together to develop antibodies to treat the novel coronavirus strain, SARS-CoV-2, that is spreading from China and causes the respiratory illness COVID-19.

Vir Biotechnology will be responsible for the design and development of antibodies that bind to spike proteins found on SARS-CoV-2. It will own commercial rights outside of China. WuXi will be responsible for developing cell lines that can manufacture the antibodies. It will own commercial rights in China.

As of 12:48 p.m. EST, the pharma stock had settled to a 55.1% gain.

A swarm of white paper airplanes being led higher by a red paper airplane.

Image source: Getty Images.

So what

Shares of Vir Biotechnology have gained 321% since the beginning of the year as investors have speculated about the company's potential to develop treatments for SARS-CoV-2. The company has previously announced the identification of two antibodies with activity against the novel strain of coronavirus. The idea is that the antibodies would bind to and neutralize the virus, disrupting replication and lessening the disease burden for those infected.

While many companies have announced their intention to develop treatments and vaccines against SARS-CoV-2, most of them lack a track record of success. Vir Biotechnology reported an operating loss of $114 million in the first nine months of 2019.

That said, the business ended September with $320 million in cash, which should allow it to easily divert resources to the new collaboration with WuXi Biologics.

Now what

The outbreak of SARS-CoV-2 has caught the world by surprise. It's likely to weigh on economic growth across the globe. The global pharmaceutical industry is bound to develop vaccines and treatments for the virus eventually. But investors are most likely getting a little carried away at the moment. Until companies report results from experimental therapies in real humans, investors might be better off avoiding the speculation.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
$28.60 (2.69%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.